AU6100296A - Protein particles for therapeutic and diagnostic use - Google Patents

Protein particles for therapeutic and diagnostic use

Info

Publication number
AU6100296A
AU6100296A AU61002/96A AU6100296A AU6100296A AU 6100296 A AU6100296 A AU 6100296A AU 61002/96 A AU61002/96 A AU 61002/96A AU 6100296 A AU6100296 A AU 6100296A AU 6100296 A AU6100296 A AU 6100296A
Authority
AU
Australia
Prior art keywords
particles
accordance
suspension
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61002/96A
Other languages
English (en)
Inventor
Richard C.K. Yen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemosphere Inc
Original Assignee
Hemosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/471,650 external-priority patent/US5725804A/en
Application filed by Hemosphere Inc filed Critical Hemosphere Inc
Publication of AU6100296A publication Critical patent/AU6100296A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU61002/96A 1995-06-06 1996-06-04 Protein particles for therapeutic and diagnostic use Abandoned AU6100296A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US471650 1995-06-06
US08/471,650 US5725804A (en) 1991-01-15 1995-06-06 Non-crosslinked protein particles for therapeutic and diagnostic use
US55491995A 1995-11-09 1995-11-09
US554919 1995-11-09
PCT/US1996/009458 WO1996039128A1 (en) 1995-06-06 1996-06-04 Protein particles for therapeutic and diagnostic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU48887/00A Division AU4888700A (en) 1995-06-06 2000-07-28 Protein particles for therapeutic and diagnostic use

Publications (1)

Publication Number Publication Date
AU6100296A true AU6100296A (en) 1996-12-24

Family

ID=27043520

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61002/96A Abandoned AU6100296A (en) 1995-06-06 1996-06-04 Protein particles for therapeutic and diagnostic use

Country Status (5)

Country Link
EP (1) EP0831793A4 (ja)
JP (1) JPH11507630A (ja)
AU (1) AU6100296A (ja)
CA (1) CA2220895A1 (ja)
WO (1) WO1996039128A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE284714T1 (de) * 1996-10-21 2005-01-15 Quadrant Drug Delivery Ltd Plättchen-ersatzmittel und geeignetes konjugations-herstellungsverfahren
EP0860167A1 (en) * 1997-01-30 1998-08-26 Robert Gurny RNA-and DNA- based active agents in nanoparticles
JP2002503254A (ja) * 1997-06-05 2002-01-29 ヘモスフィア,インコーポレイテッド フィブリノゲンをコーティングしたミクロスフィア
GB9724143D0 (en) 1997-11-14 1998-01-14 Andaris Ltd Pharmaceutical conjugate
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP2280004B1 (en) * 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
JP2008523829A (ja) * 2004-12-22 2008-07-10 ノボザイムス アクティーゼルスカブ 血清アルブミンの組換え生成
CA2618439A1 (en) * 2005-08-12 2007-02-22 Astellas Pharma Inc. Technique for stabilization of yw753 reparation
DE102006011507A1 (de) 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
US9504641B2 (en) * 2011-09-10 2016-11-29 Richard C. K. Yen Therapy to reduce extravasation damage
US10603287B2 (en) * 2016-07-20 2020-03-31 Ptlnv, Llc, Series Three (3) Albumin nanosphere preparations to control bleeding from surgical operations
KR101167285B1 (ko) * 2011-11-18 2012-07-23 에이앤펩주식회사 피부 미백 활성을 갖는 나이아신-펩타이드 및 그의 용도
WO2019007355A1 (en) 2017-07-05 2019-01-10 Jiangyin Usun Pharmaceutical Co., Ltd. ANTI-INFLAMMATORY USE OF PEPTIDE
CN112236440A (zh) * 2018-05-28 2021-01-15 江阴贝瑞森制药有限公司 新的药物用途
CN113797861B (zh) * 2021-09-16 2024-03-29 江苏月旭新材料科技有限公司 一种羟丙基葡聚糖微球及其制备方法和用途
WO2024169972A1 (en) 2023-02-13 2024-08-22 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565559A (en) * 1968-03-11 1971-02-23 Sumitomo Chemical Co Process for making microcapsules
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4325937A (en) * 1977-09-22 1982-04-20 Battelle Development Corporation Microbial insecticide
CH652599A5 (de) * 1981-08-28 1985-11-29 Solco Basel Ag Verfahren zur herstellung physiologisch abbaubarer kolloidaler, human-serumalbumin enthaltender produkte und ihre verwendung.
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5104674A (en) * 1983-12-30 1992-04-14 Kraft General Foods, Inc. Microfragmented ionic polysaccharide/protein complex dispersions
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
JPS6418439A (en) * 1987-07-14 1989-01-23 Nippon Oils & Fats Co Ltd Powdery fat coated with crosslinked coating and its manufacture
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
JPH0813750B2 (ja) * 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤
US5374441A (en) * 1992-02-04 1994-12-20 Rutgers, The State University Of New Jersey Heat stable fat substitute compositions and process

Also Published As

Publication number Publication date
EP0831793A4 (en) 2000-11-15
JPH11507630A (ja) 1999-07-06
CA2220895A1 (en) 1996-12-12
EP0831793A1 (en) 1998-04-01
WO1996039128A1 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
US6391343B1 (en) Fibrinogen-coated particles for therapeutic use
US5725804A (en) Non-crosslinked protein particles for therapeutic and diagnostic use
US5616311A (en) Non-crosslinked protein particles for therapeutic and diagnostic use
AU6100296A (en) Protein particles for therapeutic and diagnostic use
Hussain et al. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat
Yin et al. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution
US6025337A (en) Solid microparticles for gene delivery
Yin et al. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin
US20020142046A1 (en) Protein particles for therapeutic and diagnostic use
Verrecchia et al. Non-stealth (poly (lactic acid/albumin)) and stealth (poly (lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers
Yoo et al. Biodegradable nanoparticles containing protein‐fatty acid complexes for oral delivery of salmon calcitonin
Eniola et al. Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes
Nobs et al. Surface modification of poly (lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods
US7897563B2 (en) Use of oligomers and polymers for drug solubilization, stabilization, and delivery
Lin et al. Preparation and in vitro characterization of HSA-mPEG nanoparticles
Liu et al. Oral drug delivery with nanoparticles into the gastrointestinal mucosa
Lin et al. Preparation of surface-modified albumin nanospheres
JPH04504404A (ja) 治療薬および診断薬の内皮および上皮取り込み、および障害部位への局在化のための生物付着薬物担体
CN102048695A (zh) 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
JP2008528446A (ja) タンパク質ドラッグデリバリ用ナノ粒子
MX2008011428A (es) Nanoparticulas cargadas con principio activo basadas en proteinas hidrofilas.
EP0938299A1 (en) Methods for the production of protein particles useful for delivery of pharmacological agents
Jiao et al. Preparation and in vitro evaluation of heparin-loaded polymeric nanoparticles
AU4888700A (en) Protein particles for therapeutic and diagnostic use
JP7549575B2 (ja) 経口投与用生物学的ポリマーの製剤

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted